Adenomyoepithelioma

A mixed epithelial and myoepithelial neoplasm usually encountered within the breast. It is a multinodular lesion presenting with a bicellular pattern of proliferating epithelial and myoepithelial cells, which are regularly distributed in the glandular structures.

Also Known As:

Networked: 73 relevant articles (0 outcomes, 1 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Breast Neoplasms (Breast Cancer)
4.	Adenoid Cystic Carcinoma (Cylindroma)
5.	Noninfiltrating Intraductal Carcinoma (DCIS)

Experts

1.	Nayak, Anupma: 3 articles (01/2020 - 12/2018)
2.	Tran, Tien Anh N: 2 articles (06/2021 - 06/2020)
3.	Pareja, Fresia: 2 articles (01/2021 - 01/2018)
4.	Reis-Filho, Jorge S: 2 articles (01/2021 - 01/2018)
5.	Weigelt, Britta: 2 articles (01/2021 - 01/2018)
6.	Masuda, Shinobu: 2 articles (10/2020 - 02/2016)
7.	Baraban, Ezra: 2 articles (01/2019 - 12/2018)
8.	Bleiweiss, Ira J: 2 articles (01/2019 - 12/2018)
9.	Jaffer, Shabnam: 2 articles (01/2019 - 12/2018)
10.	Lubin, Daniel: 2 articles (01/2019 - 12/2018)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Adenomyoepithelioma:

1.	methylamphotericin B (AME)IBA 08/01/2017 - "This study set out to investigate the clinical diagnosis and treatment strategies for malignant breast adenomyoepithelioma (AME), thus increasing the clinical knowledge on such disease. " 05/01/2023 - "An excisional biopsy was performed, and the final pathology was consistent with a benign adenomyoepithelioma (AME). " 03/01/2023 - "Over the last 20 years, 120 patients were histologically diagnosed with breast adenomyoepithelioma (AME) at our institution. " 01/01/2022 - "In this article, we present a case of a young female who presented with a 2 cm lump in the breast without other clinical symptoms, which revealed a benign adenomyoepithelioma (AME). " 01/01/2020 - "Breast adenomyoepithelioma (AME) is rare. "
2.	Phenobarbital (Luminal)FDA Link 01/01/2018 - "In adenomyoepithelioma, PIK3CA mutation was present in both luminal epithelial and myoepithelial cells, whereas p16 loss was found only in the latter. " 01/01/2022 - "Malignant adenomyoepithelioma (MAME) of the breast is an extremely rare breast malignancy, in which they arise from either luminal epithelial or myoepithelial components, or both. " 05/01/2013 - "Adenomyoepithelioma of the breast is an uncommon tumor characterized by dual differentiation into luminal cells and myoepithelial cells. " 01/01/2004 - "Adenomyoepithelioma is a biphasic neoplasm of the breast, composed of both luminal epithelial and myoepithelial cells. " 01/01/1988 - "Histologically, the tumor demonstrated the characteristic bicellular differentiation of luminal epithelial and myoepithelial cells reported in previous adenomyoepitheliomas of the breast. "
3.	Estrogen ReceptorsIBA 01/01/2020 - "Here, we describe a case of carcinomatous transformation of both epithelial and myoepithelial cells in an estrogen receptor-negative adenomyoepithelioma caused by amplification of MYC. " 01/01/2021 - "A subset of low-grade triple-negative disease has been shown to harbor highly recurrent if not pathognomonic genetic alterations, such as ETV6-NTRK3 fusion gene in secretory carcinomas, the MYB-NFIB fusion gene, MYBL1 rearrangements or MYB gene amplification in adenoid cystic carcinomas, and HRAS Q61 hotspot mutations coupled with mutations in PI3K pathway genes in estrogen receptor-negative adenomyoepitheliomas. " 01/01/2018 - "Here we show through whole-exome and targeted massively parallel sequencing analysis that whilst estrogen receptor (ER)-positive adenomyoepitheliomas display PIK3CA or AKT1 activating mutations, ER-negative adenomyoepitheliomas harbor highly recurrent codon Q61 HRAS hotspot mutations, which co-occur with PIK3CA or PIK3R1 mutations. "
4.	Proteins (Proteins, Gene)FDA Link 09/01/1995 - "Thus, as distinct from adenomyoepithelioma, the tumor is composed of pluripotential elements which are the exception from the rule of the IF proteins tissue specificity. " 04/01/2009 - "We describe the clinical history of a woman following excision of a benign adenomyoepithelioma which recurred years later as a radioresistant malignant myoepithelioma with high levels of ataxia telangiectasia mutated protein and mutant p53 (Cys135Phe). "
5.	CalponinsIBA 02/01/2015 - "In choosing immunohistochemical markers, any of the seven markers are useful, but combining HMWCK and any one of α-SMA, calponin, and p63 would be a good panel for the diagnosis of adenomyoepithelioma. " 02/01/2015 - "There was no significant difference in the expression of α-SMA, calponin, p63, and CD10 in neoplastic myoepithelial cells of adenomyoepithelioma regardless of spindle or clear cell types. " 01/01/2023 - "WT1, p63, and calponin immunostains were performed on normal and lesional tissues from the breast (adenosis, sclerosing adenosis, lactating adenoma, nipple adenoma, tubular adenoma, adenomyoepithelioma, and adenoid cystic carcinoma [ACC]), skin (cutaneous mixed tumor, hidradenoma, spiradenoma, and ACC), and salivary gland (pleomorphic adenoma and ACC). " 02/01/2015 - "To determine which immunohistochemical markers are useful for the identification of neoplastic myoepithelial cells in adenomyoepithelioma of the breast, the expression of seven myoepithelial markers (α-smooth muscle actin (α-SMA), calponin, p63, CD10, cytokeratin 5/6, cytokeratin 14, and S-100) was examined in 19 lesions from 16 patients. "
6.	ErbB Receptors (EGF Receptor)IBA 10/16/2020 - "Adenomyoepithelioma with a human epidermal growth factor receptor 2-fluorescence in situ hybridization-confirmed ductal carcinoma in situ component: A case report and review of the literature."
7.	Keratin-5 (Keratin 5)IBA 02/01/2015 - "To determine which immunohistochemical markers are useful for the identification of neoplastic myoepithelial cells in adenomyoepithelioma of the breast, the expression of seven myoepithelial markers (α-smooth muscle actin (α-SMA), calponin, p63, CD10, cytokeratin 5/6, cytokeratin 14, and S-100) was examined in 19 lesions from 16 patients. "
8.	Keratin-14 (Keratin 14)IBA 02/01/2015 - "To determine which immunohistochemical markers are useful for the identification of neoplastic myoepithelial cells in adenomyoepithelioma of the breast, the expression of seven myoepithelial markers (α-smooth muscle actin (α-SMA), calponin, p63, CD10, cytokeratin 5/6, cytokeratin 14, and S-100) was examined in 19 lesions from 16 patients. "
9.	Activins (Activin)IBA 08/01/1999 - "A cross-sectional study comparing the expression of inhibin/activin subunits alpha, betaA and betaB in surgical specimens from women undergoing reductive mammoplasty (classified, according to the phase of the menstrual cycle, as follicular, luteal, or postmenopausal), and patients submitted to lumpectomy for fibrocystic disease, benign (intraductal papilloma, adenomyoepithelioma, and hamartoma) or malignant breast neoplams (intraductal, intralobular, and invasive carcinoma). "
10.	Matrix Metalloproteinases (MMPs)IBA 08/01/2003 - "We immunohistochemically compared benign myoepithelial tumors (adenomyoepitheliomas [AMEs]) and metaplastic matrix-producing (MMP-CA) and spindle cell (MSC-CA) carcinomas of the breast to identify helpful diagnostic markers. "

Therapies and Procedures

1.	Simple Mastectomy 03/01/2002 - "Subsequent simple mastectomy and wide local excision were performed on cases 1 and 2, respectively, revealing focal carcinomatous transformation in the adenomyoepitheliomas. " 11/01/2021 - "We present our findings and experience from cases of metastatic small cell lung carcinoma to the breast, IgG-4 related breast disease, breast implant associated anaplastic large cell lymphoma, granular cell tumor, pleomorphic sarcoma, adenomyoepithelioma, post-radiation angiosarcoma, and breast carcinoma after risk-reducing total mastectomy. "
2.	Segmental Mastectomy (Lumpectomy) 03/01/2017 - "Breast conserving surgery and sentinel lymph node biopsy for the invasive ductal carcinoma together with resection of the adenomyoepithelioma was performed. " 08/01/1999 - "A cross-sectional study comparing the expression of inhibin/activin subunits alpha, betaA and betaB in surgical specimens from women undergoing reductive mammoplasty (classified, according to the phase of the menstrual cycle, as follicular, luteal, or postmenopausal), and patients submitted to lumpectomy for fibrocystic disease, benign (intraductal papilloma, adenomyoepithelioma, and hamartoma) or malignant breast neoplams (intraductal, intralobular, and invasive carcinoma). "
3.	Drug Therapy (Chemotherapy) 11/01/2010 - "Breast MRI for monitoring images of an "adenomyoepithelioma with malignant features", before, during, and after chemotherapy." 01/01/2015 - "Following histopathological, immunohistochemical, and clinical evaluations, the patients were diagnosed as follows: pseudoangiomatous stromal hyperplasia (PASH), bilateral desmoid-type fibromatosis (FM), adenomyoepithelioma (AME), myofibroblastoma (MFB), malignant phyllodes tumor (MF), high-grade AS, post-chemotherapy osteosarcoma (OS) + Paget's disease, and metaplastic carcinoma (MC). "
4.	Breast Implants (Breast Implant) 11/01/2021 - "We present our findings and experience from cases of metastatic small cell lung carcinoma to the breast, IgG-4 related breast disease, breast implant associated anaplastic large cell lymphoma, granular cell tumor, pleomorphic sarcoma, adenomyoepithelioma, post-radiation angiosarcoma, and breast carcinoma after risk-reducing total mastectomy. "
5.	Mammaplasty (Breast Reconstruction) 08/01/1999 - "A cross-sectional study comparing the expression of inhibin/activin subunits alpha, betaA and betaB in surgical specimens from women undergoing reductive mammoplasty (classified, according to the phase of the menstrual cycle, as follicular, luteal, or postmenopausal), and patients submitted to lumpectomy for fibrocystic disease, benign (intraductal papilloma, adenomyoepithelioma, and hamartoma) or malignant breast neoplams (intraductal, intralobular, and invasive carcinoma). "